The high-dose aldesleukin "select" trial: A trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma

Clinical Cancer Research

Volumn 21, Issue 3, 2015, Pages 561-568

  McDermott, David F ^a   Cheng, Su Chun ^b   Signoretti, Sabina ^c   Margolin, Kim A ^d   Clark, Joseph I ^e   Sosman, Jeffrey A ^f   Dutcher, Janice P ^g   Logan, Theodore F ^h   Curti, Brendan D ⁱ   Ernstoff, Marc S ^j   Appleman, Leonard ^k   Wong, Michael K K ^l   Khushalani, Nikhil I ^l   Oleksowicz, Leslie ^m   Vaishampayan, Ulka N ⁿ   Mier, James W ^a   Panka, David J ^a   Bhatt, Rupal S ^a   Bailey, Alexandra S ^a   Leibovich, Bradley C ^o   Kwon, Eugene D ^o   Kabbinavar, Fairooz F ^p   Belldegrun, Arie S ^p   Figlin, Robert A ^q   Pantuck, Allan J ^p   Regan, Meredith M ^b   Atkins, Michael B ^r   more..

^a DANA FARBER HARVARD CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e LOYOLA UNIVERSITY CHICAGO   (United States)

^f VANDERBILT INGRAM CANCER CENTER   (United States)

^g OUR LADY OF MERCY MEDICAL CENTER   (United States)

^h INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ EARLE A CHILES RESEARCH INSTITUTE   (United States)

^j DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^k UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^l ROSWELL PARK CANCER INSTITUTE   (United States)

^m Lawrence and Memorial Hospital   (United States)

ⁿ KARMANOS CANCER INSTITUTE   (United States)

^o MAYO CLINIC   (United States)

^p Santa Monica UCLA Medical Center   (United States)

^q Cedars Sinai's Samuel Oschin Comprehensive Cancer Institute   (United States)

^r GEORGETOWN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALDESLEUKIN; CARBONATE DEHYDRATASE IX; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; INTERLEUKIN 2; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; EXPERIMENTAL DESIGN; HISTOPATHOLOGY; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; IMMUNOHISTOCHEMISTRY; INTEGRATED SELECTION MODEL; KIDNEY FAILURE; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MEMORIAL SLOAN KETTERING CANCER CENTER SCORE; MIDDLE AGED; NEPHRECTOMY; NONBIOLOGICAL MODEL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE MODEL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TUMOR REGRESSION; UNIVERSITY OF CALIFORNIA LOS ANGELES SURVIVAL AFTER NEPHRECTOMY AND IMMUNOTHERAPY SCORE; VALIDATION STUDY; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; METASTASIS; MORTALITY; PATHOLOGY; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RECOMBINANT PROTEINS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84961289871     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1520     Document Type: Article

References (42)

1. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-96.
2. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, et al. Randomized study of high-dose and low-dose interleukin- 2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-32.
3. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-41.
4. Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1989;7:486-98.
5. Negrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R, et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007;110:2468-77.
6. Negrier S, Caty A, Lesimple T, Douillard JY, Escudier B, Rossi JF, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d'Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2000;18:4009-15.
7. Royal RE, Steinberg SM, Krouse RS, Heywood G, White DE, Hwu P, et al. Correlates of response to IL2 therapy in patients treated formetastatic renal cancer and melanoma. Cancer J Sci Am 1996;2:91-8.
8. Figlin R, Gitlitz B, Franklin J, Dorey F, Moldawer N, Rausch J, et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am 1997;3 Suppl 1:S92-7.
9. Leibovich BC, Han KR, Bui MH, Pantuck AJ, Dorey FJ, Figlin RA, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;98:2566-75.
10. Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 1999;17:523-8.
11. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002;20:2376-81.
12. Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005;28:488-95.
13. Shablak A, Sikand K, Shanks JH, Thistlethwaite F, Spencer-Shaw A, Hawkins RE. High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer. J Immunother 2011;34:107-12.
14. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003;9:802-11.
15. Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;11:3714-21.
16. Dudek AZ, Yee RT, Manivel JC, Isaksson R, Yee HO. Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin- 2 therapy for metastatic renal cell carcinoma. Anticancer Res 2010;30:987-92.
17. de Martino M, Klatte T, Seligson DB, LaRochelle J, Shuch B, Caliliw R, et al. CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. J Urol 2009;182:728-34.
18. Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009;27:2645-52.
19. Cho DC, Sosman JA, Sznol M, Gordon MS, Hollebecque A, Hamid O, et al. Clinical activity, safety, and biomarkers ofMPDL3280A, an engineered PDL1 antibody in patients with metastatic renal cell carcinoma(mRCC). JClin Oncol 31, 2013 (suppl; abstr 4505).
20. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
21. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004;101:17174-9.
22. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96.
23. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66:3381-5.
24. Belldegrun A, Webb DE, Austin HA III, Steinberg SM, Linehan WM, Rosenberg SA. Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy. J Urol 1989;141:499-503.
25. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-9.
26. Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 1997;158:1691-5.
27. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966-70.
28. Birkhauser FD, Pantuck AJ, Rampersaud EN, Wang X, Kroeger N, Pouliot F, et al. Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience. Cancer J 2013;19:189-96.
29. Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, et al. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer 2014;110:2821-8.
30. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931-9.
31. Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 formetastatic melanoma or renal cell carcinoma. J Clin Oncol 2006;24:1169-77.
32. Lenardo M, Chan KM, Hornung F, McFarland H, Siegel R, Wang J, et al. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 1999;17:221-53.
33. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed bymultiregion sequencing. N Engl J Med 2012;366:883-92.
34. Bahamon B, Signoretti S. Tissue Biomarkers in Renal Cell Carcinoma: Intermediate Endpoints in the Selection of Targeted Agents for RCC. In "Renal Cell Carcinoma: Biology, Prognostic Factors and Therapeutic Targets." Edited byRathmell Kimryn, Rini Brian, Figlin Robert A. New York: Springer; 2012. pp. 69-89.
35. Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 2010;70:9554-61.
36. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
37. Grosso J HC, Inzunza D, Cardona DM, Simon JS, Gupta AK, Sankar V, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol 31, 2013 (suppl; abstr 3016).
38. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra37.
39. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
40. Gajewski TF, Fuertes M, Spaapen R, Zheng Y, Kline J. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol 2011;23:286-92.
41. McDermott DF, Drake CD, Sznol M, Choueiri TK, Powderly JD, Smith DC, et al. Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with previously treated, metastatic renal cell carcinoma (mRCC). J Clin Oncol 30, 2012 (suppl;abstr 4505).
42. Oken MM, Creech RH, Tormey DC. Toxicity and response criteria of the ECOG. Am J Clin Oncol 1982;5:649-55.